Developments in non-flow cytometry

A novel, inexpensive, and easily performed non-flow cytometric method called CD4 Select was presented by Thai researchers in 2008. It counts CD4 cells using an automatic haematology analyser (equipment used for performing complete blood counts). The results for absolute CD4 counts and CD4 lymphocyte percentage correlated closely with results from standard flow cytometry. The CD4 Select can be used in small or rural settings and offers relatively high sample throughput, while being less labour intensive than other non-flow cytometric methods.

The test reagent, CD4 Select, is generated by binding the MT4 monoclonal antibody (mAb) to ferrous beads. MT4 binds strongly to the CD4 molecule on CD4 lymphocytes (CD4 T-cells), but weakly or not at all to the CD4 on monocytes, so MT4 can be used to tag CD4 T-cells in blood samples with a high degree of specificity. When the CD4 Select reagent is combined with the blood sample, CD4 cells become bound to the beads and are then magnetically removed from the sample. The percentage of CD4 lymphocytes can be calculated by subtracting the lymphocyte count in this CD4-depleted sample from the total lymphocyte count in a second, unaltered sample from the same patient; the absolute CD4 lymphocyte count is then derived from the percentage. Turnaround time is less than one hour.1

A Ugandan study found that although the use of dynabeads and hydrospheres each underestimated CD4 lymphocyte count compared with flow cytometry, in resource-limited areas with small daily volume, manual bead-based assays might be an alternative to flow cytometry.2

References

  1. Srithanaviboonchai K et al. Novel low-cost assay for the monitoring of CD4 counts in HIV-infected individuals. J Acquir Immune Def Syndr 47(2):135-139, 2008
  2. Lutwama F et al. Evaluation of Dynabeads and Cytospheres compared with flow cytometry to enumerate CD4+ T cells in HIV-infected Ugandans on antiretroviral therapy. J Acquir Immune Defic Syndr 48(3):297-303, 2008
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.